Fat Effects in Women With Metabolic Syndrome

NCT ID: NCT01093560

Last Updated: 2011-08-05

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2011-09-30

Brief Summary

Among 10 premenopausal women with Metabolic Syndrome:

Specific Aim 1: Compare the effects of acute fat feeding on flow mediated dilation (FMD) as measured by brachial artery reactivity among three fat challenges (saturated fat vs. monounsaturated fat (MUFA) vs. polyunsaturated fat (PUFA)at 4 hours post feeding. Hypothesis Saturated fat feeding will impair FMD but MUFA and PUFA feeding will not.

Specific Aim 2: Compare the effects of acute feeding on vascular inflammation as measured by VCAM and sICAM among three fat challenges at 3 1/2 hours post feeding.

Hypothesis: Saturated fat feeding will increase vascular inflammation but MUFA and PUFA will not.

Conditions

Metabolic Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: TRIPLE

Study Groups

young women with MetS

1. Saturated fat (control)

2. n-3 Polyunsaturated fat (experimental)

3. monounsaturated fat

Group Type: EXPERIMENTAL

fat feeding

Intervention Type: DIETARY_SUPPLEMENT

Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.

Interventions

fat feeding

Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Female,
• 18-50 years of age,
• Pre-menopausal,
• Weight stable for at least 3 months,
• Not planning to lose or gain weight for 3 months,
• Meets the following 3/5 criteria for metabolic syndrome:

• increased blood sugar
• increased blood fats (triglycerides),
• increased blood pressure,
• decreased good cholesterol (HDL-C).
• increased waist circumference,

Exclusion Criteria

• History of diabetes mellitus
• Fasting glucose ≥ 126 mg/dL
• History of cardiovascular disease (peripheral vascular disease, coronary artery disease, cerebrovascular disease)
• Pregnant or planning a pregnancy within the study period
• Fasting triglycerides > 500 mg/dL
• Currently taking lipid lowering medications**
• Oral or patch hormone contraception**
• Currently taking vaso-active (blood pressure) medications**
• SBP ≥ 140 and/or DBP ≥90 mm Hg or taking blood pressure lowering Rx
• Chronic use of aspirin (prn use is allowed)
• Chronic use of non-steroidal anti-inflammatory medications (prn use is allowed)
• Tobacco use within 6 months of starting study
• Participation in another clinical trial within the last 30 days
• History of active gall bladder disease
• History of digestive or malabsorptive disease requiring treatment or surgery
• Moderate to severe lactose intolerance
• Milk Allergy
• Walnut Allergy or Nut Allergy
• Coconut allergy

(**) Drugs within the following classifications are exclusionary: Lipid lowering, beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, calcium channel blockers, alpha blockers, nitrates, hormone contraception includes patch or oral hormone contraception (Hormone containing IUDs or vaginal rings are okay)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University of Washington

OTHER

Sponsor Role: lead

Responsible Party

University of Washington

Principal Investigators

Pathmaja Paramsothy, MD, MS

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

University of Washington

Seattle, Washington, United States

Countries

United States

Other Identifiers

36899-D

Identifier Type: -

Identifier Source: org_study_id